Jefferies Expects a 25% Move in Athira Pharma (ATHA) Post Aducanumab Approval
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $40.00 price target on Athira Pharma (NASDAQ: ATHA) on the belief ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
